Background: Hemophilia A is a chronic condition that requires meticulous treatment and
management. Patient preferences for prophylactic treatment can substantially influence …

Introduction Gene therapy has shown promise in clinical trials for patients with haemophilia,
but patient preference studies have focused on factor replacement treatments. Aim We …

Abstract Background and Objectives Caregivers routinely inform medical and regulatory
decision making in rare pediatric diseases. While differences in treatment preferences …

This study pioneers a comprehensive methodology to quantify occupants' willingness to
reduce energy consumption behaviors, specifically focusing on student occupants within a …

Objectives This study evaluated the treatment preferences among patients and caregivers
for moderate or severe hemophilia A in Taiwan. Methods This cross-sectional study used a …

Background: The patient voice is an important consideration in the availability and choice of
pharmaceuticals–however, how to capture this complex area and apply it formally within …

Background US patients with hemophilia A can receive prophylaxis with extended half-life
recombinant factor VIII (rFVIII) products, including efmoroctocog alfa (fragment crystallizable …